• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Nephrology

Belatacept provides better long-term immunosuppression in kidney transplantation than cyclosporine: The BENEFIT study

byShayna BejaimalandShaidah Deghan, MSc. MD
January 31, 2016
in Nephrology, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Seven years after transplantation, patient and kidney graft survival and function were significantly higher with belatacept than cyclosporine based immunosuppressants.

2. The cumulative frequencies of serious adverse events were similar across both belatacept and cyclosporine groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Renal transplant immunosuppressive therapies usually include calcineurin-inhibitors, like cyclosporine, with antiproliferative drugs and glucocorticoids. These regimens have shown improved outcomes in the short-term however may not provide adequate allograft protection over the long-term. Belatacept, a selective costimulation blocker, was developed to increase long-term immunosuppression without the toxic effects of calcineurin inhibitors. The interim results of the BENEFIT trial showed that belatacept was associated with similar patient and graft survival when compared to cyclosporine however had significantly improved renal function. This report summarizes the final efficacy and safety of belatacept up to 7 years after transplantation in the BENEFIT population.

Both belatacept regimens resulted in a 43% reduction in risk of death or graft loss as compared to cyclosporine. There was also a significant increase in estimated glomerular filtration rate (eGFR) with belatacept therapy whereas cyclosporine treatment was associated with a decline in eGFR. Frequencies of adverse events were similar across all treatment groups. Strengths of this study include use of intention-to-treat analysis and long follow-up with adequate retention. A major limitation of this study is the lack of comparison to tacrolimus, the current standard-of-care calcineurin inhibitor, as opposed to cyclosporine.

Click to read the study, published today in NEJM

Relevant Reading: A phase III study of Belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT Study)

RELATED REPORTS

#VisualAbstract Half of the organ transplant recipients who develop skin cancers post-transplant will develop at least another skin cancer within two years

Postponing renal replacement therapy may result in poor clinical outcomes in patients with severe acute kidney injury 

#VisualAbstract: Oxygenated hypothermic perfusion reduces post-kidney transplant complications

In-Depth [randomized controlled trial]: This international, randomized, single-blind, parallel-group with active control study started patient enrollment in January 2006 with initial primary endpoint analysis in June 2008 and followed patients for 84 months. Kidney transplant recipients were randomly assigned to a more intensive (MI) belatacept regimen, a less intensive (LI) regimen or a cyclosporine-based regimen and followed for renal function (eGFR), patient and graft survival as well as adverse events.

From the 660 patients who were treated, 153 of 219 MI patients, 163 of 226 LI patients and 131 of 215 cyclosporine patients were included in the final analysis. There was a significant reduction in the composite risk of death or graft loss in both MI and LI belatacept regimens (HR=0.57, 95% [CI] 0.35-0.95; p=0.02 and HR=0.57, 95% [CI] 0.35-0.94; p=0.02, respectively). However, when analyzed individually these rates, while showing a trend towards belatacept, were non-significant. The mean eGFR increased significantly during follow-up for both belatacept regimens however decreased with cyclosporine-based regimen (p<0.001).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: BelataceptCyclosporinekidney transplant
Previous Post

Increased vitamin D supplementation during pregnancy may not decrease childhood wheezing

Next Post

Maintenance dialysis initiation largely driven by physician and clinical setting factors

RelatedReports

#VisualAbstract Half of the organ transplant recipients who develop skin cancers post-transplant will develop at least another skin cancer within two years
StudyGraphics

#VisualAbstract Half of the organ transplant recipients who develop skin cancers post-transplant will develop at least another skin cancer within two years

October 29, 2021
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

Postponing renal replacement therapy may result in poor clinical outcomes in patients with severe acute kidney injury 

June 25, 2021
#VisualAbstract: Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease
StudyGraphics

#VisualAbstract: Oxygenated hypothermic perfusion reduces post-kidney transplant complications

December 16, 2020
Solitary kidney not associated with contrast-induced nephropathy
Gastroenterology

Proton pump inhibitor use associated with increased mortality risk in kidney transplant patients

June 25, 2020
Next Post
APOL1 variants linked to increased risk of renal disease among black patients

Maintenance dialysis initiation largely driven by physician and clinical setting factors

Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]

Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]

Record-based algorithm may improve lung cancer screening follow-up

Higher prevalence of malpractice claims associated with prior paid claims and medical specialty

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Mental Health
  • #VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
  • #VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.